The Medicare GLP-1 Bridge is a temporary federal program running from July 1, 2026 through December 31, 2027 that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight-loss medications for a flat $50 monthly copay. It runs outside your Part D plan entirely — your plan does not have to opt in, and a previous Part D denial does not disqualify you. Eligibility is based on BMI at the time you started GLP-1 therapy, plus specific medical conditions.
Key takeaways
Standard Medicare Part D still excludes weight-loss drugs. The Bridge is a separate, temporary program.
Three medications are covered, and only certain formulations of one of them.
Eligibility is judged on your BMI when you started the medication, not your BMI today.
If you have type 2 diabetes, sleep apnea, or MASH, you go through Part D instead, not the Bridge.
There is no appeals process. Getting the prior authorization right the first time matters.
For as long as Medicare has existed, it has not paid for drugs used for weight loss. That exclusion is written into federal law and it has not changed. What has changed is that CMS created a separate temporary program that sits alongside Part D and covers these medications for people who meet its criteria. It is called the Medicare GLP-1 Bridge, and I have had a steady stream of patients asking about it since it opened.
What the Bridge actually is
It is a short-term CMS demonstration, not a permanent benefit. It opened on July 1, 2026 and is currently scheduled to run through December 31, 2027.
The important structural detail: it operates outside the normal Part D coverage and payment flow. Your Part D plan does not have to participate for you to use it, and CMS uses a single central processor to handle prior authorization, claims, and payment to pharmacies. Practically, that means your plan's formulary decisions do not apply here, and a prior authorization your Part D plan previously denied for the same drug does not rule you out.
Which medications are covered
Three products, when prescribed to reduce excess body weight and maintain weight reduction:
Wegovy — all formulations, including both the weekly injection and the oral tablet
Foundayo — all formulations
Zepbound — the KwikPen formulation only
That Zepbound detail catches people out. The single-dose vial and single-dose pen formulations are not covered through the Bridge — only the KwikPen. Pen needles are not covered either and have to be purchased separately.
Ozempic and Mounjaro are not part of the Bridge. They are approved for type 2 diabetes rather than weight management, and they are covered through standard Part D.
Who qualifies
You need to be enrolled in an eligible Part D plan type, be 18 or older, be taking the medication for weight management alongside ongoing structured nutrition and physical activity, and meet one of three clinical tiers:
BMI of 35 or higher on its own, with no additional diagnosis required.
BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension (above 140 systolic or 90 diastolic despite two blood pressure medications), or chronic kidney disease stage 3a or above.
BMI of 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
The detail most people miss: you must have met the criteria when you started GLP-1 therapy, not today. If you began treatment two years ago at a BMI of 37 and you are now at 34, you still qualify under the first tier — and that includes people who started before the Bridge existed, or before they were on Medicare. Bring your old records if you started somewhere else.
Who does not qualify
If you have type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH, those are already covered indications under regular Part D. You are expected to go through your Part D plan, and you are not eligible for the Bridge even if you meet the BMI criteria.
There is a subtler version of this. If the medication is being prescribed in order to reduce your cardiovascular risk rather than to reduce weight, that prescription belongs with your Part D plan too. The prior authorization requires the prescriber to attest that the drug is for weight reduction, and that attestation is made under penalty of perjury, so it is not a box anyone should tick loosely.
Plan types matter too. Standalone Part D plans and most Medicare Advantage plans with drug coverage qualify, as do Special Needs Plans and employer or union group plans. Private fee-for-service plans, cost contracts, PACE, and a few others do not, unless you also have a standalone Part D plan.
How the process actually runs
The order of operations here is unusual, and getting it wrong causes most of the delays:
Your prescriber sends the prescription to the pharmacy first.
The pharmacy submits the claim to the Bridge, which establishes that you exist in the system.
The pharmacy then sends the prior authorization request back to the prescriber, usually within 24 to 72 hours.
The prescriber completes and submits it.
A decision comes back within about 72 hours, mailed to you and sent to the prescriber.
Submitting the prior authorization before the pharmacy has filed a claim produces a "patient not found" error, which is a common and entirely avoidable source of lost time.
One more thing worth knowing: there is no appeals process under the Bridge. If a request is denied, the prescriber can resubmit with corrected or additional information, but there is no formal appeal the way there is with a Part D denial. That makes accurate documentation on the first submission more important here than almost anywhere else in insurance.
Common questions
My Part D plan already denied Wegovy. Am I out of luck?
No. The Bridge runs on its own criteria, outside your Part D plan, and a prior denial does not disqualify you. A Part D denial is not required either — the claim can go straight to the Bridge.
Does the $50 count toward my Part D out-of-pocket maximum?
No. Because the Bridge sits outside the Part D benefit, the copay does not count toward your plan's deductible or annual out-of-pocket cap. Office visits are separate and bill through Medicare as usual.
What happens when the program ends?
It is currently scheduled to end December 31, 2027, and what replaces it has not been settled. That is a real consideration when deciding whether to start, because stopping a GLP-1 commonly leads to weight regain. It is a conversation worth having at the beginning rather than in late 2027.
Do I have to change doctors to use it?
No. A prescriber does not even need to be enrolled in Medicare to write the prescription or submit the prior authorization, as long as they are not on the CMS Preclusion List. Your existing doctor can handle it.
How we can help
At FloMD Primary Care in Cypress, TX, we handle Bridge prior authorizations as part of our medical weight management program. That means confirming which tier you qualify under, documenting your BMI at the time you started therapy, and making sure the paperwork is right the first time given there is no appeal.
If you are on Medicare and have been told for years that weight-loss medication was not covered, this is worth a conversation. Our guides to how GLP-1 medications work and what side effects to expect cover the clinical side, and we have written separately about insurance coverage for weight loss injections for patients on commercial plans.
Program details can change during a demonstration. Current official information is published by CMS.
